+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Bipolar Disorder Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4787518
  • Report
  • May 2019
  • Region: Global
  • 114 pages
  • Mordor Intelligence
until Mar 31st 2020
1 of 4


  • AbbVie Inc.
  • Allergan PLC
  • AstraZeneca Plc
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
Market Overview

The major factors for the growth of the bipolar disorder market include the increasing prevalence of the bipolar disorder, rising initiatives by government institutes to increase the awareness, and technological advancements.

There is an increasing prevalence of bipolar disorder owing to the various risk factors such as high stress, substance abuse, and others. According to the estimates of the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, the prevalence of bipolar disorder across the world varies from 0.3 to 1.2% by country. In 2017 around 46 million people in the world had bipolar disorder, with 52% and 48% being female and male, respectively. The typical age of onset is the late teens or the early 20s, and a history of depression is common in people diagnosed with bipolar. Men and women are affected by bipolar disorder in equal numbers. In women, the first episode is typically manic, while men typically experience a depressive episode first. Hence, the rise in the cases of the disease and the increasing need to manage them effectively has led to the growth of the bipolar disorder market.

Scope of the Report

As per the scope of this report, bipolar disorder is a mental illness marked by extreme shifts in mood. Symptoms may include an extremely elevated mood called mania, and also episodes of depression. Bipolar disorder is also known as bipolar disease or manic depression. People with bipolar disorder may have trouble managing everyday life tasks at school or work, or maintaining relationships. There’s no cure, but there are many treatment options available that can help with managing the symptoms.

Key Market Trends

Antipsychotic Drugs is expected to be the Fastest Growing Segment Over the Forecast Period

Antipsychotic medications are used as a short-term treatment for bipolar disorder to control psychotic symptoms, such as hallucinations, delusions, or mania symptoms. These symptoms may occur during acute mania or severe depression. Some also treat bipolar depression, and several have demonstrated long-term value in preventing future episodes of mania or depression. In people with bipolar disorder, antipsychotics are also used "off label" as sedatives, for insomnia, for anxiety, and/or for agitation. Often, they are taken with a mood-stabilizing drug and can decrease the symptoms of mania until mood stabilizers take full effect. Some antipsychotics seem to help stabilize moods on their own. As a result, they may be used alone as a long-term treatment for people who do not tolerate or respond to lithium and anticonvulsants. A few antipsychotic drugs include aripiprazole (Abilify), asenapine (Saphris), cariprazine (Vraylar), clozapine (Clozaril), lurasidone (Latuda), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and ziprasidone (Geodon). Hence, due to the above-mentioned reasons, the market for antipsychotic drugs is expected to grow and further lead to the growth in the Bipolar Disorder Market.

North America is Expected to Dominate the Market

North America is found to hold a major share for the bipolar disorder market and is expected to show a similar trend over the forecast period, without significant fluctuations. Due to the increasing cases of bipolar disorder and the presence of better healthcare infrastructure, the market is expected to witness high growth over the forecast period. According to the data published by the National Alliance on Mental Illness, around 1 in 5 adults in the United States experiences mental illness in a given year. Hospitalization is required for severe episodes of mania and depression to protect the patients from injuring themselves or others. According to the NIMH, bipolar I disorder is characterized in part by manic symptoms that are so severe that the person needs immediate hospital care. There is a huge need to tackle bipolar disorder, as it is an increasing problem, and hence, the market for bipolar disorder is expected to grow during the forecast period.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are AbbVie Inc., Allergan PLC, AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline Plc, Janssen Pharmaceuticals Inc., Novartis AG, Otsuka Holdings Co. Ltd, and Pfizer Inc.
Note: Product cover images may vary from those shown
2 of 4


  • AbbVie Inc.
  • Allergan PLC
  • AstraZeneca Plc
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Bipolar Disorder
4.2.2 Rising initiative by Government Institutes to Increase the Awareness
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Side Effects Associated with Bipolar Drugs
4.3.2 Misdiagnosis of Bipolar Disorder
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 Mood stabilizer
5.1.2 Anticonvulsant
5.1.3 Antipsychotic Drug
5.1.4 Antidepressant Drug
5.1.5 Other
5.2 By Mechanism of Action
5.2.1 Selective Serotonin Reuptake Inhibitor
5.2.2 Serotonin Norepinephrine Reuptake Inhibitor
5.2.3 Tricyclic Antidepressant Drug
5.2.4 Beta Blockers
5.2.5 Others
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Allergan PLC
6.1.3 AstraZeneca Plc
6.1.4 Eli Lilly and Company
6.1.5 GlaxoSmithKline Plc
6.1.6 Janssen Pharmaceuticals Inc.
6.1.7 Novartis AG
6.1.8 Otsuka Holdings Co. Ltd
6.1.9 Pfizer Inc.

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • AbbVie Inc.
  • Allergan PLC
  • AstraZeneca Plc
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Janssen Pharmaceuticals Inc.
  • Novartis AG
  • Otsuka Holdings Co. Ltd
  • Pfizer Inc.
Note: Product cover images may vary from those shown